Advertisement

Memantine Hydrochloride

[23 June 2014]

Products Affected - Description

Namenda XR capsules, Forest
14 mg capsules, unit-dose, 100 count (NDC 00456-3414-63)
28 mg capsules, 90 count (NDC 00456-3428-90)
Titration pack, 28 capsules (NDC 00456-3400-29)

Namenda tablets, Forest
Titration pack, 49 tablets (NDC 00456-3200-14)
5 mg tablets, 60 count (NDC 00456-3205-60)
5 mg tablets, unit dose, 100 count (NDC 00456-3205-63)
10 mg tablets, 60 count (NDC 00456-3210-60)
10 mg tablets, unit dose, 100 count (NDC 00456-3210-63)

Reason for the Shortage

  • Forest cannot provide a reason for the shortage of Namenda XR capsules.
  • Forest plans to discontinue all Namenda immediate-release tablets on August 15, 2014. Forest will continue to market Namenda oral solution and Namenda XR extended-release capsules. Forest states the reason for discontinuing the Namenda immediate-release tablets is to focus on the Namenda XR extended-release capsules.

Available Products

Namenda XR capsules, Forest
7 mg capsules, 30 count (NDC 00456-3407-33)
14 mg capsules, 30 count (NDC 00456-3414-33)
14 mg capsules, 90 count (NDC 00456-3414-90)
21 mg capsules, 30 count (NDC 00456-3421-33)
28 mg capsules, 30 count (NDC 00456-3428-33)
28 mg capsules, unit-dose, 100 count (NDC 00456-3428-63)
Namenda oral solution, Forest
2 mg/mL, 360 mL bottle (NDC 00456-3202-12)

Estimated Resupply Dates

  • Forest has Namenda XR titration pack, 14 mg capsules in unit-dose, and 28 mg capsules in 90 count bottles on back order and the company cannot estimate a release date.
  • Forest has all Namenda tablet presentations currently available. Product can be dispensed until supplies are depleted.

Updated

June 23, 2014; April 23, 2014; March 31, 2014; February 19, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement